By showing that hepatic IL-6 spillover impacts pancreatic immunity and can be pharmacologically corrected through IL-6R antagonism, we propose a targetable inter-organ immune axis that provides a novel therapeutic framework, particularly in the context of preventing β-cell failure and diabetes progression in MASH. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatohepatitis.